The risk of chronic kidney disease in a metabolically healthy obese population

Kidney International

Volumn 88, Issue 4, 2015, Pages 843-850

  Jung, Chang Hee ^a   Lee, Min Jung ^a   Kang, Yu Mi ^a   Hwang, Jenie Y ^a   Kim, Eun Hee ^a   Park, Joong Yeol ^a   Kim, Hong Kyu ^a   Lee, Woo Je ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

chronic kidney disease; metabolic health; obesity

Indexed keywords

ADULT; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; AGED; BIOLOGICAL MODEL; CHI SQUARE DISTRIBUTION; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY, METABOLICALLY BENIGN; PATHOPHYSIOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; SOUTH KOREA; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; OBESITY, METABOLICALLY BENIGN; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84942988718     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.183     Document Type: Article

References (57)

1. Stefan N, Artunc F, Heyne N et al. Obesity and renal disease: not all fat is created equal and not all obesity is harmful to the kidneys. Nephrol Dial Transplant 2014 (e-pub ahead of print).
2. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79.
3. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013; 14: 219-227.
4. Primeau V, Coderre L, Karelis AD et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011; 35: 971-981.
5. Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616.
6. Hee Jung C, Jung Lee M, Mi Kang Y et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. J Clin Endocrinol Metab 2014; 100: 934-941.
7. Hinnouho GM, Czernichow S, Dugravot A et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J 2014; 36: 551-559.
8. Hinnouho GM, Czernichow S, Dugravot A et al. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care 2013; 36: 2294-2300.
9. Ogorodnikova AD, Kim M, McGinn AP et al. Incident cardiovascular disease events in metabolically benign obese individuals. Obesity (Silver Spring) 2012; 20: 651-659.
10. Ruster C, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant 2013; 28: iv8-14.
11. Natali A, Boldrini B, Baldi S et al. Impact of mild to moderate reductions of glomerular filtration rate on coronary artery disease severity. Nutr Metab Cardiovasc Dis 2014; 24: 681-688.
12. Roy SK, Cespedes A, Li D et al. Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium. Vasc Health Risk Manag 2011; 7: 719-724.
13. Hermans MM, Henry R, Dekker JM et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol 2007; 18: 1942-1952.
14. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402-1407.
15. Hanks LJ, Tanner RM, Muntner P et al. Metabolic subtypes and risk of mortality in normal weight, overweight, and obese individuals with CKD. Clin J Am Soc Nephrol 2013; 8: 2064-2071.
16. Wildman RP, Muntner P, Reynolds K et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008; 168: 1617-1624.
17. Chen S, Zhou S, Wu B et al. Association between metabolically unhealthy overweight/obesity and chronic kidney disease: the role of inflammation. Diabetes Metab 2014; 40: 423-430.
18. Wang C, Liang K, Zhang X et al. Metabolic abnormalities, but not obesity, contribute to the mildly reduced eGFR in middle-aged and elderly Chinese. Int Urol Nephrol 2014; 46: 1793-1799.
19. Sesti G, Succurro E, Arturi F et al. IGF-1 levels link estimated glomerular filtration rate to insulin resistance in obesity: A study in obese, but metabolically healthy, subjects and obese, insulin-resistant subjects. Nutr Metab Cardiovasc Dis 2011; 21: 933-940.
20. Carlson MD, Morrison RS. Study design, precision, and validity in observational studies. J Palliat Med 2009; 12: 77-82.
21. Cignarelli M, Lamacchia O. Obesity and kidney disease. Nutr Metab Cardiovasc Dis 2007; 17: 757-762.
22. Ejerblad E, Fored CM, Lindblad P et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-1702.
23. Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for endstage renal disease. Ann Intern Med 2006; 144: 21-28.
24. Gelber RP, Kurth T, Kausz AT et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005; 46: 871-880.
25. Iseki K, Ikemiya Y, Kinjo K et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65: 1870-1876.
26. Chagnac A, Weinstein T, Korzets A et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817-F822.
27. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension 1995; 26: 610-615.
28. McLaughlin T, Abbasi F, Lamendola C et al. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 2007; 167: 642-648.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
30. Meigs JB, Wilson PW, Fox CS et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912.
31. Gomez-Ambrosi J, Catalan V, Rodriguez A et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care 2014; 37: 2813-2821.
32. Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. J Hypertens 2004; 22: 1051-1055.
33. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-562.
34. Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol 2013; 33: 14-22.
35. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008; 294: F685-F696.
36. Praga M, Hernandez E, Herrero JC et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111-2118.
37. Prasad GV. Metabolic syndrome and chronic kidney disease: current status and future directions. World J Nephrol 2014; 3: 210-219.
38. Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes 2014; 7: 421-435.
39. Thomas G, Sehgal AR, Kashyap SR et al. Metabolic syndrome and kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6: 2364-2373.
40. Okada R, Yasuda Y, Tsushita K et al. The number of metabolic syndrome components is a good risk indicator for both early-and late-stage kidney damage. Nutr Metab Cardiovasc Dis 2014; 24: 277-285.
41. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850.
42. Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.
43. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919.
44. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 2005: S87-S93.
45. Joles JA, Kunter U, Janssen U et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 2000; 11: 669-683.
46. Velho S, Paccaud F, Waeber G et al. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr 2010; 64: 1043-1051.
47. Zuo L, Ma YC, Zhou YH et al. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 463-472.
48. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
49. Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727.
50. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 2003; 107: 370-371.
51. Jung CH, Lee MJ, Hwang JY et al. Association of metabolically healthy obesity with subclinical coronary atherosclerosis in a Korean population. Obesity (Silver Spring) 2014; 22: 2613-2620.
52. American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care 2015; 38: S8-S16.
53. Furusyo N, Koga T, AiMet al. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia 2011; 54: 3028-3036.
54. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
55. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
56. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J 2011; 35: 561-566.
57. Elliott AC, Hynan LS. A SAS(R) macro implementation of a multiple comparison post hoc test for a Kruskal-Wallis analysis. Comput Methods Programs Biomed 2011; 102: 75-80.